Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,061 to 1,080 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers. | NPJ Breast Cancer | 2022 | 35538088 | PubTator, text mining | PubMed |
| Trovafloxacin drives inflammation-associated drug-induced adverse hepatic reaction by changing macrophage polarization. | Toxicol In Vitro | 2022 | 35537566 | PubTator, text mining | PubMed |
| Genetic Analysis of Lung Cancer and the Germline Impact on Somatic Mutation Burden. | J Natl Cancer Inst | 2022 | 35511172 | PubTator, text mining | PubMed |
| Transcriptome analysis provides critical answers to the "variants of uncertain significance" conundrum. | Hum Mutat | 2022 | 35510381 | PubTator, text mining | PubMed |
| Genetic clinicians' confidence in BOADICEA comprehensive breast cancer risk estimates and counselees' psychosocial outcomes: A prospective study. | Clin Genet | 2022 | 35508697 | PubTator, text mining | PubMed |
| Alterations in homologous recombination repair genes in prostate cancer brain metastases. | Nat Commun | 2022 | 35504881 | PubTator, text mining | PubMed |
| Detection of Structural Variations and Fusion Genes in Breast Cancer Samples Using Third-Generation Sequencing. | Front Cell Dev Biol | 2022 | 35493102 | PubTator, text mining | PubMed |
| Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro. | PLoS One | 2022 | 35486574 | PubTator, text mining | PubMed |
| Utility of germline multi-gene panel testing in patients with endometrial cancer. | Gynecol Oncol | 2022 | 35483985 | PubTator, text mining | PubMed |
| Genetics and genomics of bone marrow failure syndrome. | Blood Res | 2022 | 35483932 | PubTator, text mining | PubMed |
| Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures. | Biomed Res Int | 2022 | 35480139 | PubTator, text mining | PubMed |
| Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland. | Sci Rep | 2022 | 35469032 | PubTator, text mining | PubMed |
| Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification. | BMC Med | 2022 | 35468796 | PubTator, text mining | PubMed |
| Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience. | Front Genet | 2022 | 35464868 | PubTator, text mining | PubMed |
| Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair. | Front Oncol | 2022 | 35463312 | PubTator, text mining | PubMed |
| Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR. | BMC Med | 2022 | 35462552 | PubTator, text mining | PubMed |
| Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy. | J Med Imaging Radiat Oncol | 2022 | 35460184 | PubTator, text mining | PubMed |
| Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants. | Genes (Basel) | 2022 | 35456503 | PubTator, text mining | PubMed |
| Identification and Somatic Characterization of the Germline PTEN Promoter Variant rs34149102 in a Family with Gastrointestinal and Breast Tumors. | Genes (Basel) | 2022 | 35456450 | PubTator, text mining | PubMed |
| Identification of a Cancer-Predisposing Germline POT1 p.Ile49Metfs*7 Variant by Targeted Sequencing of a Splenic Marginal Zone Lymphoma. | Genes (Basel) | 2022 | 35456397 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=54